

ALASKA MEDICAID
Prior Authorization Criteria

**Baxfendy®
(baxdrostat)**

FDA INDICATIONS AND USAGE¹

Baxfendy® is an aldosterone synthase inhibitor indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

APPROVAL CRITERIA^{1,2,3}

1. Patient meets FDA labeling age requirement **AND**;
2. Patient has a diagnosis of hypertension **AND**;
3. Patient blood pressure remains above target goal outlined in expert consensus hypertension guidelines **AND**;
4. One or more of the following applies
 - a. Patient blood pressure remains above goal while on triple agent therapy with agents from three different antihypertensive therapy classes for a minimum of 4 weeks
 - b. Patient blood pressure remains above goal and patient has a documented clinical failure to tolerate triple antihypertensive therapy with agents from three different antihypertensive therapy classes **AND**;
5. Patient will continue treatment with one or more other antihypertensive agents while taking Baxfendy®

DENIAL CRITERIA¹

1. Failure to meet approval criteria **OR**;
2. The patient is or will be on monotherapy with Baxfendy® **OR**;
3. Patient eGFR is < 45 mL/min

CAUTIONS¹

- Electrolyte disturbances, including hyperkalemia and hyponatremia, have been reported.
- The safety of Baxfendy in pregnancy has not been established.

ALASKA MEDICAID
Prior Authorization Criteria

DURATION OF APPROVAL

- Initial Approval: up to 3 months
- Reauthorization Approval: up to one year

QUANTITY LIMIT

- 34 tablets/34 days

REFERENCES / FOOTNOTES:

1. Baxfendy (baxdrostat) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2026.
2. Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025; 393(14): 1363-1374
3. Jones DW, Ferdinand KC, Taer SJ, et al. 2025
AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025; 82(10): e212-e316.